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Leishmania species are the causative agents of the leishmaniases, a spectrum of neglected tropical diseases. Amastigote stage
parasites exist within macrophages and scavenge host factors for survival, for example, Leishmania species utilise host sphingolipid
for synthesis of complex sphingolipid. In this study L. mexicana endocytosis was shown to be significantly upregulated in
amastigotes, indicating that sphingolipid scavenging may be enhanced. However, inhibition of host sphingolipid biosynthesis had
no significant eﬀect on amastigote proliferation within amacrophage cell line. In addition, infection itself did not directly influence
host biosynthesis. Notably, in contrast to L. major, L. mexicana amastigotes are indicated to possess a complete biosynthetic
pathway suggesting that scavenged sphingolipids may be nonessential for proliferation. This suggested that Old and New World
species diﬀer in their interactions with the macrophage host. This will need to be considered when targeting the Leishmania
sphingolipid biosynthetic pathway with novel therapeutics.
1. Introduction
Leishmania species are insect vector-borne kinetoplastid pro-
tozoan pathogens causing a wide spectrum of neglected
tropical diseases (the leishmaniases—cutaneous, mucocuta-
neous, and visceral) in humans across the globe. Moreover,
the spread and severity of disease are exacerbated by its status
as an important coinfection in AIDS patients [1]. Leishmania
species exhibit a digenetic lifecycle: (a) existing as flagellated
promastigotes within the sand fly vector; (b) following
an insect bite and uptake by professional phagocytic cells,
especially macrophages, diﬀerentiating into the aflagellate
amastigote form. Within the host macrophage the para-
site proliferates within acidic, fusogenic, endosome-derived
phagolysosomes [2]. This compartment intersects with the
phagosomal and autophagosomal pathwaysmeaning that the
parasites have access to the rich mix of nutrients resulting
from degradation of phagocytosed macromolecules within
the lytic environment of the phagolysosome. However,
residency within such a compartment could also lead to
contact with components of the host major histocompati-
bility complex (MHC), subsequent macrophage activation,
and parasite killing. To overcome this certain species of
Leishmania sequester and degrade MHC molecules [3,
4]; presumably this occurs via endocytosis although the
mechanism has not been characterised. Endocytosis is also
the process by which nutrients can be taken into the parasite,
for example, L. amazonensis amastigotes were reported to
endocytose transferrin from the phagolysosome [5]. How-
ever other species, including L. mexicana, do not show this
behaviour [6]. Low-density lipoprotein [7] and haemoglobin
[8] have also been shown to be endocytosed by Leishmania
promastigote forms.
Sphingolipids are amphipathic lipids consisting of a sph-
ingosine backbone with a long-chain fatty acid and a polar
alcohol as attachments. Ceramide is an unmodified sphin-
golipid that functions as a secondary messenger in ubiq-
uitous, eukaryotic signalling mechanisms. Modified (com-
plex) sphingolipids are major components of the outer
leaflet of eukaryotic plasma membranes believed to be
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involved, with sterols, in the formation of microdomains
or lipid rafts. Rafts are proposed to function in a diverse
array of processes from the polarised traﬃcking of lipid-
modified proteins, to the assembly of signal transduction
complexes [9]. The first, rate-limiting, enzyme in sphin-
golipid biosynthesis is serine palmitoyltransferase (SPT).
SPT catalyses the condensation of L-serine and palmitoyl
CoA to form 3-ketodihydrosphinganine. Subsequently, N-
acetylation of sphingoid base in the endoplasmic reticulum
(ER) leads to the formation of ceramide, which is converted
to complex sphingolipids (e.g., sphingomyelin SM or inos-
itol phosphorylceramide—IPC) via sphingolipid synthases.
The animal sphingolipid synthase, SM synthase (SMS),
transfers phosphorylcholine from phosphatidylcholine (PC)
to ceramide to give SM; in contrast yeast, plants, and
the kinetoplastid protozoan parasite Leishmania utilise IPC
synthase to catalyse the formation of IPC via the transfer
of phosphorylinositol from phosphatidylinositol (PI) to
(phyto)ceramide [10]. This non-mammalian enzyme has
long been established as a drug target for antifungals
[11], and more recently, the sphingolipid synthase from
Trypanosoma brucei (a kinetoplastid relative of Leishmania)
has been demonstrated to be essential [12, 13].
Intriguingly, biosynthesis of sphingoid base and
ceramide, precursors of complex sphingolipids, is absent and
nonessential for the proliferation of L. major amastigotes
within phagolysosomes in a model animal system [14, 15].
However, intramacrophage amastigotes synthesize the com-
plex sphingolipid IPC de novo utilising precursors from al-
ternative, host sources and maintain this lipid species at
equivalent cellular levels to promastigotes [15]. It has
been shown that L. donovani stimulate host macrophages
to upregulate the production of ceramide, a substrate
for IPC synthase [16] and a downstream product
of SPT. Furthermore, recent work has identified the
L. major SMase (LmjISCL) and shown it to be essential
for pathogenicity in an animal model. This indicated that
the generation of ceramide from host SM, via LmjISCL,
is key to proliferation within the phagolysosome [17, 18].
Taken together, these studies indicated that L. major (and
perhaps L. donovani, another Old World species) scavenges
host sphingolipids to generate ceramide for amastigote
proliferation, pathogenicity, and IPC biosynthesis.
Like amastigote Leishmania, the bacterial pathogen Cox-
iella burnetti (the aetiologic agent of Q fever) replicates
within an acidified endocytic compartment and scavenges
the sphingolipid SM from the plasmamembrane via endocy-
tosis [19]. In this work we sort to establish whether Leishma-
nia employs a similar strategy to acquire and utilise essential
host sphingolipids.
2. Materials and Methods
2.1. Cell Culture. Leishmania mexicana (MNYC/BZ/62/
M379) promastigotes were maintained at 26◦C in Schnei-
der’s media (Sigma Aldrich) pH7, supplemented with 15%
foetal bovine sera (FBS, Biosera Ltd). Promastigotes were
diﬀerentiated to amastigote forms in Schneider’s media with
20% FBS at pH 5.5 and 32◦C according to the published
protocol [20]. The continuous murine macrophage cell line
RAW264.7 was maintained in DMEM (Gibco-BRL) with
10% FBS, at 37◦C and 5%CO2. The cytoxicity of myriocin
(Sigma Aldrich) was established using the AlamarBlue (Invit-
rogen) assay according to manufacturer’s protocol and as
previously [21, 22]. The eﬃcacy of myriocin was confirmed
using a yeast diﬀusion assay [23].
2.2. Metabolic Labelling. L. mexicana axenic promastigotes
and amastigotes (107 mL−1) were incubated in serum-free
Schneider’s media for 30 minutes before labeling in the
same with 5 μMof BSA conjugated BODIPY FL C5-ceramide
(Invitrogen) at 26◦C and 32◦C, respectively, for 2 hours.
Promastigote parasites were similarly labeled for 16 hours
in DMEM (ICN) supplemented with 10% FCS (Gibco BRL)
and 20mCi mL−1 [myo-3H]-inositol (102Cimmol−1 Am-
ersham) [14]. For serine-containing lipid analysis axenic
amastigotes (5×107 mL−1) were incubated for 45 minutes in
MEM Eagle (Sigma Aldrich) then labeled for 8 hours in the
same medium containing 20mCi mL−1 [3H]-L-serine (20Ci
mmol−1; ICN) [14]. Lipids were extracted and analysed as
previously described [23].
2.3. Endocytosis Assay. L. mexicana cells were washed three
times using warm serum-free media and counted using a
Neubauer haemocytometer. 107 cells were then incubated
with 50 μgmL−1 3 k Texas RedDextran (Invitrogen) in 500 μL
of serum-free media for 2 hours at 32◦C. Controls were
incubated on ice. Cells were subsequently washed 5 times
with ice cold PBS and fixed with 3.7% formaldehyde. After
washing, cells were resuspended in 500 μL of PBS and the
fluorescence quantified using a plate reader (FLx800TM,
BioTek; 590/20 Ex 645/40 Em). Observation of cells by
fluorescence microscopy indicated that the dextran had been
taken up by the parasites.
2.4. Macrophage Infection. 1× 105 RAW264.7 murine ma-
crophages in DMEM were allowed to adhere to coverslips
within each well of a 24-well tissue culture plate (Nunc) and
then incubated for 24 hours in appropriate media (DMEM
with 10% FBS or with 1% Nutridoma, Roche) with or
withoutmyriocin. L. mexicana amastigotes were then applied
at a ratio of 10 : 1 in media and the infection allowed to
proceed for 48 hours at 32◦C and 5%CO2, with daily changes
of media with myriocin where appropriate.
2.5. Expression Analyses. Denatured parasite lysates were
separated and immunoblotted as described [24] and the
filters probed with mouse anti-LmjLCB2 or rabbit anti-
LmjNMT polyclonal primary antibodies [14] at 1 : 1000,
followed by horseradish peroxidase-conjugated secondary
antibodies (Sigma-Aldrich). Complexes were detected using
the ECL system (Amersham Pharmacia). For the mRNA
analyses, total RNA from equivalent numbers of 48 hours
infected, or noninfected, RAW264.7 cells were extracted
using the RNeasy kit (Qiagen) according to the man-
ufacturer’s protocol. Following DNase treatment (RQ1,
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Promega) cDNA was synthesized using the ImProm-II
Reverse Transcription System (Promega) according to man-
ufacturer’s protocol. Quantitative PCR was performed in
a Rotor-Gene RG3000 (Corbett Research) using SYBR
Green Jump-Start Taq Ready Mix (Sigma Aldrich) ac-
cording to the manufacturer’s instructions. The murine
MmLcb2 (encoding subunit 2 of SPT) was amplified us-
ing the primer pair-5′AGGTGGATATCATGGAGAGA 3′
and 5′GATCCAGTGTTCCTCGC 3′. The reference gene,
MmCasc3, was amplified using primers as previously [25].
The qPCR was carried out in triplicate on 3 replicates
with annealing temperature 52◦C for MmLcb2 and 55◦C for
MmCasc3.
3. Results and Discussion
3.1. Endocytosis in Promastigote and Amastigote L. mexicana.
Like Leishmania species, Trypanosoma brucei (which causes
the neurological NTD African sleeping sickness) is a kineto-
plastid parasite. However, whereas the pathogenic amastigote
forms of Leishmania species shelter within macrophages,
the mammalian form of T. brucei proliferates extracellularly
within the bloodstream of the host. Here it must avoid the
full force of the immune system, and the switching of the pre-
dominant surface molecule, Variable Surface Glycoprotein
(VSG), is key to this. Endocytosis of VSG is an important part
of this antigenic variation and immune evasion. Notably, the
rate of endocytosis in bloodstream form (BSF) T. brucei is 10
times higher than in the insect stage procyclic form (PCF),
and the entire VSG coat is replaced every 7 minutes [26].
This allows the internalisation and degradation of bound
antibodies and complement factors which helps protect the
free-living parasite from the humoral immune response. This
upregulation of endocytosis is facilitated by an increase in
expression of factors involved in the uptake of VSG and
its subsequent traﬃcking and processing [27, 28]. Before
this study it remained unknown whether Leishmania species
increased their rate of endocytosis on diﬀerentiation to
the mammalian amastigote form. This may be predicted
to facilitate the observed uptake of MHC and immune
avoidance [6] or allow the acquisition of host sphingolipid
for use in IPC synthesis [15, 18].
To address this the New World species L. mexicana
was employed. Unlike L. major, this species can be grown
in both promastigote and amastigote stages in axenic cell
culture [20] allowing direct comparative analyses to be
undertaken [29]. To quantify endocytosis fluorescently la-
belled dextran was utilised. Previously, dextran has been
demonstrated to be taken up, via the endocytic pathway,
by L. donovani promastigotes [30]. Here, axenic cell equiv-
alents of promastigotes (both noninfective, proliferating
procyclics, and infective, nonproliferating metacyclics) and
amastigotes were labelled under identical conditions (32◦C
in serum-free media). Dextran is measurably taken up by
procyclic promastigotes; however the quantity endocytosed
by amastigotes is more than 4 times greater (Figure 1).
Interestingly the nondiving metacyclic forms demonstrate a
similar up-regulation of this activity.
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Figure 1: The endocytosis of Texan Red labelled dextran at
32◦C measured as described and with the background (uptake in
control parasites at 0◦C) subtracted. Results from a representative
experiment, in triplicate with standard deviation shown. AFU:
arbitrary fluorescence units.
These data indicate that endocytosis is up regulated
in amastigote forms, and this could be speculated to
facilitate eﬃcient immune evasion or substrate scavenging
as discussed. The observation of similar levels of endocytic
activity in metacyclic promastigotes was surprising given
their apparent quiescence [20]. However, one may speculate
that this indicated that the machinery for this process
is acquired at this stage ready for the establishment of
amastigote infection in a mammalian host.
3.2. The Role of Host Sphingolipid Biosynthesis in L. mexi-
cana Invasion and Proliferation. To investigate IPC synthase
activity in L. mexicana, axenic promastigotes and amastigotes
were metabolically labeled with fluorescent BODIPY FL-
ceramide (Figure 2). Both cell types produced a labelled
product that comigrated with IPC, although the level in
amastigotes was relatively low reflecting the slower growth of
this form. These data indicated that L. mexicana has an active
IPC synthase in both lifecycle stages, as does L. major [15].
As discussed above, host sphingolipid must be acquired
as a source of ceramide substrate for the IPC synthase
of amastigote L. major [15]. In support of this sev-
eral studies have identified host cell glycosphingolipids in
intramacrophage amastigotes of Leishmania species [31–
33]. In addition, it has been reported that fumonisin B1
(an inhibitor of dihydroceramide synthase and ceramide
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Figure 2: HPTLC analysis of axenic procyclic promastigotes (aP)
and amastigotes (aA) metabolically labelled with BODIPY FL C5-
ceramide. IPC: inositol phosphorylceramide; Cer: ceramide.
synthesis) inhibits the replication of intramacrophage
L. donovani [34]. Utilising myriocin (a potent, specific SPT
inhibitor [35]) the role of host synthesized sphingolipids
was investigated in L. mexicana infected RAW264.7 cells, a
continuous murine macrophage cell line. The viability of
axenic promastigotes and amastigotes (data not shown) was
unaﬀected by the presence of 50 μM myriocin as previously
reported [36]. Similarly, the RAW264.7 host cells were viable
at 50 μM myriocin; levels above this lead to detachment of
cells from the tissue culture well (data not shown).
In this study 50 μMofmyriocin was applied to RAW264.7
cells for 24 hours prior to challenge with L. mexicana axenic
amastigotes at a ratio of 10 : 1. With daily application of the
drug the infection was allowed to continue for 48 hours
prior to fixation, staining, and counting as described in
Section 2. This experiment was conducted either in the
presence of full (10%) serum or in serum-reduced (1%
Nutridoma)media. The latter conditions reduce the quantity
of exogenous sphingolipid available to the RAW264.7 cells
and the intracellular parasites. Under both sets of conditions
the proportion of macrophages infected with amastigotes
is unaﬀected by the presence of myriocin (Figure 3), as is
the average number of parasites per host cell (Figure 4).
These data indicate that host sphingolipid biosynthesis and
exogenous sphingolipids are not central to the invasion and
proliferation of L. mexicana in RAW264.7macrophages.
Similarly, myriocin has been reported not to inhibit
L. major amastigote replication in cultured murine ma-
crophages [15]. In addition, unlike in L. donovani [34],
the specific ceramide synthase inhibitor fumonisin B1 had
no demonstrable aﬀect on the proliferation of intra-ma-
crophage L. major amastigotes [15]. Together, these results
indicated that host sphingolipid synthesis is not central
to the proliferation of L. major or L. mexicana amas-
tigotes within macrophages. However, it remains possible
that free ceramide is generated by the host via complex
sphingolipid catabolism—a process up regulated in L. dono-
vani infected macrophages [16]. In this study the macro-
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Figure 3: Invasion, % infected macrophages, determined 48 hours
after infection in the presence or absence of the SPT inhibitor myri-
ocin and with (FBS-DMEM) or without (FBS-reduced DMEM)
exogenous serum in the media. Results of three independent
experiments.
phages were preincubated for 24 hours with myriocin in
the absence of serum in order to deplete the host sphin-
golipid available for parasite scavenging. However, inhibition
of SPT for a length of time equivalent to the experimental
conditions employed here only leads to partial (up to∼80%)
depletion of complex sphingolipids in CHO cells [37]. This
indicated that preformed complex sphingolipids are stably
maintained in the cell membranes for some time after the
inhibition of de novo synthesis. It is possible that such lipids
could continue to be catabolised and scavenged by amas-
tigote L. mexicana.
3.3. Host and Parasite Serine Palmitoyltransferase (SPT) Ex-
pression during Macrophage Infection. Notably host de novo
sphingolipid synthesis is up regulated during L. donovani
proliferation within macrophages [16], and it is possible that
a similar eﬀect during L. mexicana infection could mask the
eﬃcacy of the SPT inhibitor myriocin. To test the hypothesis
that an increase in host sphingolipid biosynthesis, via the
up regulation of biosynthetic enzymes, is elicited by the
parasite, the levels of host MmLcb2 (encoding subunit 2 of
SPT) transcript with and without L. mexicana infection were
established using real-time qPCR. To do this normalisation
to a reference was required; of nine commonly used reference
genes in RAW264.7 cells only Casc3 was previously found to
be suitable and suﬃcient for this purpose on infection with
Mycobacterium avium [25]. Normalised to MmCasc3 expres-
sion, MmLcb2 mRNA levels were unchanged 48 hours after
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Figure 4: Proliferation, parasites per infected macrophage, deter-
mined 48 hours post infection in the presence or absence of the
SPT inhibitor myriocin, and with (FBS-DMEM) or without (FBS-
reduced DMEM) exogenous serum in the media. Results of three
independent experiments.
infection with L. mexicana (Table 1) under the conditions
described. This indicated that host sphingolipid biosynthesis
is not up regulated on infection.
These results were perhaps surprising given the previ-
ously observed down-regulation of the LmLCB2 protein in
L. major amastigote forms [14, 38], coupled with the main-
tenance of IPC biosynthesis [15] and the requirement for
catabolism of scavenged SM [17, 18]. In light of these
data it was chosen to examine the expression profile of
the L. mexicana SPT. Utilising the cross reactive anti-
LmjLCB2 antibody [14, 39] the expression of LmxLCB2 was
probed using Western blotting (Figure 5). The levels of the
constitutively expressedN-myristoyltransferase (NMT) were
used as a loading control [24].
This indicated that LmxLCB2, and so LmxSPT, is con-
stitutively expressed throughout the lifecycle of L. mexicana.
These data have been recently confirmed by proteomic anal-
yses of isolated, intra-macrophage L. mexicana amastigotes
[40]. Furthermore, metabolic labelling of axenic amastigotes
demonstrated the incorporation of tritiated serine into the
primary complex sphingolipid, IPC (Figure 6).
Taken together, these data indicated that this New World
species has a complete and active de novo sphingolipid
biosynthetic pathway in the amastigote stage, and this
contrasts with Old World L. major [14, 38]. In addition,
the possibility that myriocin may inhibit LmxSPT in intra-
macrophage L. mexicana amastigotes needs to be considered
Table 1: Expression ofMmLcb2 in infected and noninfectedmacro-
phages.
Serum Normalised MmLcb2 infected:
noninfected ± standard deviation
+ 1.04± 0.12
− 0.94± 0.12
aP aA
75
50
LCB2 NMT
aP aA
Figure 5: Lysates of 5 × 106 axenic procyclic promastigotes (aP)
and amastigotes (aA) probed with the cross reacting LmjLCB2 and
LmjNMT antibodies in a Western blot. Molecular weight markers
in kDa shown on left of image.
in relation to the data shown in Figure 4. If this compound
is able to access and inhibit the parasite enzyme in these
assays, then the results obtained would imply that both host
and parasite SPT activity are nonessential for L. mexicana
proliferation, a similar scenario to that seen in L. major [15].
3.4. Summary. These data are the first to demonstrate that
the endocytic rate of the pathogenic, amastigote stage of
Leishmania species is raised when compared with insect
stage procyclic promastigotes. This is reminiscent of the
situation in T. brucei, where endocytosis is up regulated
on diﬀerentiation to mammalian BSF parasites in order to
facilitate immune evasion [36]. This dramatic adaptation is
facilitated by an increase in expression of factors involved
in the uptake of molecules and their subsequent traﬃcking
and degradation [27, 28]. In Leishmania species proteolytic
activity is highly up regulated during diﬀerentiation from
promastigotes to amastigotes, and this coincides with the
appearance of multivesicular lysosomes (megasomes) [41].
This correlates with the uptake of host MHC molecules [41]
and, as shown here, an increase in endocytosis. However,
unlike in T. brucei, none of the known molecular machinery
of endocytosis so far studied in Leishmania species has
demonstrated any increased expression on diﬀerentiation
[24, 42]. However, a RAB-like GTPase in L. major has been
shown to have increased expression at the level of mRNA in
amastigote forms, although the role of this factor in the cell
remains unknown [43].
Both promastigotes and amastigotes of L. major [15]
and L. mexicana are able to synthesize the primary complex
sphingolipid, IPC. Old World L. major is able to do this
in the absence of de novo SPT activity, therefore is the
observed increase in endocytic activity related to an ability
to scavenge host sphingolipid for use as substrate [15]? The
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Figure 6: HPTLC analysis of axenic amastigotes (aA) metabolically
labelled with tritiated serine (Ser; 1.25×107 cell equivalent). Axenic
promastigotes (aP) similarly labelled with tritiated inositol (Inos;
5 × 106 cell equivalent) served as markers. Following fluorography
the plate was exposed to film for 15 days. PIP: phosphatidylinositol
phosphate; IPC: inositol phosphorylceramide; PI: phosphatidyli-
nositol; Cer: ceramide, migrating at solvent front.
data presented here suggest that L. mexicana amastigotes
can invade and proliferate normally when host sphingolipid
biosynthesis is inhibited and/or when the exogenous source
of lipid (serum) is removed. This suggested that the parasite
is not wholly dependant on ongoing host sphingolipid
synthesis, although residual host complex sphingolipid may
remain and be suﬃcient for the pathogen. Analyses of host
MmLcb2 and parasite LmxLCB2 expression indicated that
infection does not influence host sphingolipid biosynthesis
and that promastigote and amastigotes stages of L. mexicana
equivalently express SPT, the first enzyme in sphingolipid
biosynthesis [40]. This is in contrast to L. major where
LmjLCB2 is down regulated and nonessential for pathogen-
esis and complex sphingolipid biosynthesis [14, 38]. This
implies that there are profound diﬀerences between the
Old and New World species in terms of the relationship
between the Leishmania parasite and its mammalian host
cell. Further knowledge of these diﬀerences will be required
when considering the targeting of lipid biosynthesis for the
development of novel therapies.
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